Adaptive immune plasticity in MASH: Functional states, pathological consequences, and regulatory mechanisms.
Oct 23, 2026DOI: 10.1097/hc9.0000000000001075Journal ArticleHepatology Communications
Written by: Xiayu YuYuxuan YangLan Bai
INTRODUCTION
Metabolic dysfunction–associated steatotic liver disease (MASLD) has become one of the most common chronic liver diseases worldwide, affecting ~38% of the global population. Among these, 12%–40% of patients with isolated MASLD may progress to metabolic dysfunction–associated steatohepatitis (MASH), which is characterized by liver inflammation, hepatocyte damage, and progressive fibrosis.1–3 As the disease burden continues to rise, MASH has gradually become one of the primary indications for liver transplantation,4 placing enormous strain on healthcare systems worldwide.From a pathological perspective, MASLD represents a continuum that progresses from simple steatosis to hepatic inflammation and fibrosis. Although this pathological framework has been relatively well established, the immune mechanisms driving the progression of MASH remain incompletely understood. Traditionally, activation of the innate immune system has been considered a major initiating event in hepatic inflammation. However, accumulating evidence has revealed that the adaptive immune system also plays a critical and more finely tuned role in disease evolution.5 Metabolic reprogramming is increasingly recognized as a central hub linking hepatic metabolic dysfunction to immune dysregulation.6A substantial body of basic research has independently characterized phenotypic alterations in distinct T-cell and B-cell subsets in MASH and demonstrated the regulatory effects of glucose and lipid metabolism, epigenetic mechanisms, and the gut–liver axis on adaptive immunity. However, describing adaptive immune alterations solely in terms of changes in the abundance of individual cell subsets is insufficient to explain why the same immune lineage can exert distinct, or even opposing, effects at different stages of disease. Increasing evidence supports the concept that adaptive immunity in MASH undergoes dynamic remodeling of functional states. CD8+ T cells can adopt pathogenic, exhausted, or reparative states; CD4+ T cells can undergo functional shifts in the Th17/Treg axis; and B cells can be redistributed between regulatory and effector states. These functional states act on hepatocytes, HSCs, and myeloid cells through cytotoxicity, cytokine production, antibody responses, and intercellular interactions, thereby collectively influencing hepatocellular injury, inflammatory amplification, and fibrotic progression. Meanwhile, lipotoxicity, nutrient excess, and gut-derived signals continuously shape these immune states through metabolic reprogramming and epigenetic regulation. Therefore, integrating current evidence across 3 interconnected dimensions—functional plasticity, pathological effects, and regulatory mechanisms—may provide a unified immune–metabolic framework for understanding the roles of adaptive immunity in both the progression and resolution of MASH.
FUNCTIONAL PLASTICITY OF ADAPTIVE IMMUNE CELLS IN MASH
The adaptive immune system is an important component of chronic inflammation and tissue remodeling in MASH. Rather than viewing T and B cells as fixed and discrete subsets, accumulating evidence supports a dynamic model in which cells within the same lineage can alter their activation status, effector molecules, metabolic dependencies, and tissue-residency characteristics in response to persistent metabolic and inflammatory stimuli, thereby acquiring pro-inflammatory, immunoregulatory, functionally exhausted, or tissue-reparative functions (Table 1). Accordingly, this section summarizes representative functional states and potential transition trajectories of adaptive immune cells in MASH, providing a conceptual basis for subsequently dissecting the metabolic, epigenetic, and gut–liver axis mechanisms that drive these functional transitions.
Major adaptive immune-cell subsets in MASH
Abbreviations: APLNR, apelin receptor; BAFF, B-cell activating factor; Bregs, regulatory B cells; CD, cluster of differentiation; CXCR6, C-X-C chemokine receptor 6; FasL, Fas ligand; FOXP3, forkhead box P3; HCC, hepatocellular carcinoma; IFN-γ, interferon gamma; IgA, immunoglobulin A; IgG, immunoglobulin G; IL, interleukin; MASH, metabolic dysfunction–associated steatohepatitis; MASLD, metabolic dysfunction–associated steatotic liver disease; MHC, major histocompatibility complex; PD-1, programmed cell death protein 1; TGF-β, transforming growth factor beta; Th1, T helper 1; Th17, T helper 17; Tregs, regulatory T cells; Trm, tissue-resident memory T cells.
Under the combined influence of chronic lipotoxicity, antigenic stimulation, and persistent inflammation, T cells in the MASH liver do not maintain a single, stable functional phenotype. CD8+ T cells can transition from a persistently activated cytotoxic state toward functional dysfunction or exhaustion, while also acquiring tissue-reparative functions during disease resolution. Meanwhile, CD4+ T cells can undergo an imbalance or phenotypic shift between pro-inflammatory Th1/Th17 states and immunoregulatory Treg states. Collectively, these observations indicate that the contribution of T cells to MASH is determined not simply by their lineage identity, but by their functional state and the stage of disease.
CD8+ T cells represent one of the adaptive immune populations exhibiting pronounced functional plasticity in MASH and can adopt distinct pathogenic cytotoxic, dysfunctional/exhausted, and tissue-reparative states. Single-cell T-cell receptor (TCR) sequencing has revealed substantial clonal expansion of CD8+ T cells in MASH livers, which is associated with the severity of hepatic fibrosis.27 During disease progression, CXCR6+CD8+ T cells exhibit pronounced autoreactive and tissue-damaging characteristics.7 In parallel, CD44+CD62L− effector memory CD8+ T cells display potent cytotoxic activity and are associated with hepatocellular injury.28
Beyond these pathogenic states, a subset of CD8+ T cells can acquire dysfunctional or exhausted phenotypes, characterized by reduced effector functions and impaired immune surveillance.29 Conversely, during disease resolution, CD69+CD103− tissue-resident memory T cells (Trm) exhibit tissue-reparative properties and can promote fibrosis resolution.8 Taken together, the pathogenic, exhausted, and reparative states of CD8+ T cells are shaped by the disease stage and local microenvironment rather than representing mutually exclusive and static populations.
CD4+ T cells in MASH comprise predominantly pro-inflammatory Th1 and Th17 cells, as well as immunoregulatory Treg cells. Their functional plasticity is primarily reflected in dynamic changes in the functional states of these subsets and shifts in the Th17/Treg balance. Th1 cells are increased in MASH and are associated with exacerbated hepatic inflammation and fibrosis.9,10 Th17 cells are also markedly enriched in the livers of patients and animal models with MASH, and their expansion is associated with pathological alterations, including inflammation, insulin resistance, and lipid accumulation.11–16 Notably, a subset of CXCR3+ Th17 cells exhibits enhanced pathogenic and pro-inflammatory characteristics.30
In contrast to Th1/Th17 cells, Tregs primarily contribute to immune tolerance and tissue protection.17 However, their abundance, stability, or immunosuppressive capacity can be compromised in MASH. Moreover, a subset of Tregs can acquire a Th17-like pro-inflammatory phenotype.18 Such phenotypic instability may further exacerbate the functional imbalance between Th17 and Treg cells and may help explain the divergent effects of Tregs on MASH progression reported across different studies.31 Overall, CD4+ T cells in MASH exhibit a functional shift from protective immunoregulation toward pro-inflammatory effector activity.
B cells likewise exhibit substantial functional plasticity in MASH, encompassing distinct pro-inflammatory/antigen-presenting, antibody-mediated effector, and immunoregulatory states. Activated B cells possess potent antigen-presenting capacity and can promote T-cell activation.19 B2 cells and germinal center B cells exhibit pro-inflammatory properties and pathogenic antibody responses, which are associated with hepatic inflammation and tissue injury.20–22 Enhanced responses of BAFF-responsive B cells and plasma cells have also been linked to disease progression.9,32 In addition, APLNR+ B cells exhibit prominent tissue-infiltrating and pro-fibrotic characteristics,23 whereas IgA+ B cells can exert immunosuppressive effects and have been associated with impaired antitumor immune surveillance during the progression from MASH to hepatocellular carcinoma (HCC).21,24,25 In contrast to these effector B-cell populations, regulatory B cells (Bregs) predominantly exert anti-inflammatory and tolerogenic functions, but their abundance or functional capacity is frequently reduced in MASH.22,26,33 Thus, the contribution of B cells to MASH is not uniformly pathogenic but instead depends on the functional composition and balance among pro-inflammatory, antibody-mediated effector, and regulatory states.
Collectively, the functional heterogeneity of adaptive immunity in MASH is characterized by distinct CD8+ T-cell states ranging from pathogenic and exhausted to reparative functions; an imbalance in CD4+ T-cell functions between Th1/Th17-mediated pro-inflammatory activity and Treg-mediated immunoregulation; and the functional diversification of B cells toward pro-inflammatory, antibody-mediated effector, or regulatory states.
The impact of adaptive immune plasticity on the course of MASH lies primarily in the ability of distinct functional states to exert direct effects on hepatocytes, HSCs, and myeloid cells through their effector molecules, thereby altering hepatic inflammation, metabolic homeostasis, fibrosis, and immune surveillance. CD8+ T cells act predominantly through cytotoxic killing, inflammatory cytokine release, and direct regulation of HSCs; CD4+ T cells modulate hepatocellular metabolism and cell death, myeloid-cell recruitment, and inflammatory intensity primarily through IFN-γ, IL-17A, and immunosuppressive cytokines; whereas B cells regulate T cells, macrophages, and HSCs through antigen presentation, cytokines, antibodies, and immune complexes. Thus, functional reprogramming of adaptive immune cells can be directly translated into hepatocellular injury, metabolic imbalance, persistent inflammation, and fibrosis, while under specific functional states, adaptive immunity can also contribute to tissue repair and fibrosis resolution.
During MASH progression, liver-resident CXCR6+CD8+ T cells can acquire autoreactive properties and induce hepatocellular death through P2X7-associated metabolic sensing and effector mechanisms involving FasL, independently of classical MHC-I–mediated antigen recognition.7 In addition, CD44+CD62L− effector memory CD8+ T cells accumulate in MASH livers and exhibit increased expression of cytotoxic effector molecules such as GZMB and PRF1, indicating the acquisition of an enhanced cytotoxic state.28 CD8+ T-cell–mediated hepatocellular injury can further promote the release of inflammatory mediators and damage-associated molecular patterns (DAMPs), including TNF-α, IL-6, and IFN-γ, thereby recruiting and activating myeloid cells and promoting HSC activation.34 This establishes a feed-forward circuit that amplifies hepatic inflammation and fibrogenesis. Thus, pathogenic CD8+ T cells can convert T-cell cytotoxicity into sustained hepatic injury and pro-fibrotic responses through 2 interconnected pathways: direct hepatocellular killing and inflammation-mediated HSC activation.
CD8+ T-cell dysfunction primarily compromises immune surveillance in MASH. As the disease progresses, CD8+ T cells can gradually acquire an exhausted phenotype, accompanied by impaired effector functions and reduced capacity to eliminate aberrant cells. Studies have shown that downregulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), a key enzyme involved in prostaglandin degradation, is closely associated with dysregulated lipid metabolism and lipid accumulation in the hepatic microenvironment. Excessive uptake of these accumulated fatty acids by CD8+ T cells impairs mitochondrial function, as evidenced by reduced mitochondrial membrane potential, increased PD-1 expression, and decreased production of TNF-α and IFN-γ. This lipotoxic remodeling ultimately promotes CD8+ T-cell exhaustion and substantially compromises immune surveillance.35 Consequently, abnormal hepatocytes may evade immune clearance and persist within the damaged liver, potentially increasing the risk of progression from MASH to HCC.
Conversely, during disease resolution, CD69+CD103− Trm cells can localize to and interact with activated HSCs through a CCR5-dependent mechanism and subsequently induce HSC apoptosis through FasL-mediated death signaling, thereby reducing the population of pro-fibrotic cells and promoting fibrosis resolution.8 Therefore, the effects of CD8+ T cells on MASH outcomes depend critically on their predominant cellular targets and effector mechanisms. Aberrant cytotoxicity toward hepatocytes promotes tissue injury, insufficient immune surveillance against aberrant cells increases the risk of disease deterioration, whereas selective elimination of activated HSCs favors fibrosis reversal.
Th17 cells represent an important effector population through which CD4+ T cells promote inflammation and metabolic injury in MASH. Th17-derived IL-17A induces the expression of chemokines such as CXCL1 and CXCL10, thereby promoting the recruitment of myeloid cells.11 IL-17A can also act directly on hepatocytes and induce the upregulation of GSDMD through a STAT3–IFI16-associated pathway, leading to pyroptotic cell death accompanied by mitochondrial dysfunction, impaired fatty acid oxidation, and triglyceride accumulation.36 In addition, IL-17 can downregulate the expression of stearoyl-CoA desaturase 1 (SCD-1) in hepatocytes, thereby disrupting monounsaturated fatty acid synthesis and exacerbating lipid accumulation.37 Thus, IL-17 signaling transmits Th17 effector activity across 3 interconnected pathological processes—immune-cell recruitment, hepatocellular death, and lipid metabolic dysfunction—thereby reinforcing the interplay between local inflammation and metabolic injury. IFN-γ produced by Th1 cells further promotes hepatic inflammation and pro-fibrotic responses, acting together with Th17-derived signals to sustain the inflammatory microenvironment in MASH.9,10
Impaired Treg function primarily affects MASH by relieving immune-mediated restraints on inflammation. Under physiological conditions, Treg-derived IL-10 and TGF-β can restrain autoreactive CD8+ T cells and Th1/Th17 effector responses, attenuate IFN-γ–associated tissue injury, and contribute to the maintenance of hepatocellular fatty acid metabolism.38 IL-10 also suppresses the production of IL-1β, TNF-α, IL-6, and iNOS by Kupffer cells, thereby limiting myeloid inflammation and improving hepatic insulin signaling.39 When Treg stability is compromised, and Tregs acquire Th17-like features, the resulting pathological effects are not simply attributable to a reduction in protective Treg abundance but instead involve two simultaneous changes. First, the loss of IL-10/TGF-β–mediated immunosuppression weakens the restraint on CD8+ T cells, Th1/Th17 cells, and Kupffer cells. Second, cells that acquire the capacity to produce IL-17 can directly contribute to hepatocellular injury and inflammatory-cell recruitment.18 Thus, the functional shift of Tregs toward a Th17-like phenotype can simultaneously result in the loss of immunosuppressive activity and the acquisition of pro-inflammatory effector functions, thereby amplifying the contribution of CD4+ T cells to hepatic inflammation and metabolic injury in MASH.
Beyond antibody production, B cells regulate MASH through antigen presentation, cytokine secretion, and interactions with T cells and myeloid cells. TNF-α produced by B2 cells can not only stimulate HSCs and exacerbate hepatic collagen deposition,19 but also act directly on hepatocytes to suppress peroxisome proliferator–activated receptor-α (PPAR-α) and its downstream target genes, thereby impairing fatty acid oxidation and mitochondrial β-oxidation, increasing triglyceride accumulation, and exacerbating hepatic steatosis.40 Activated B cells upregulate major histocompatibility complex class I and II (MHC-I/II) molecules and CD86, thereby enhancing antigen presentation and T-cell costimulation, particularly promoting Th1 responses.19 Activated CD4+ T cells can subsequently produce IFN-γ, which further promotes M1-like macrophage activation.41 Meanwhile, B-cell–derived BAFF promotes B-cell expansion, plasma-cell maturation, and Th1 activation,9,32 thereby sustaining inflammatory interactions between B cells and T cells.
The humoral functions of B cells can further establish a direct link between adaptive immunity and myeloid cells and HSCs through antibodies and immune complexes. Pathogenic IgG produced by germinal center B cells and plasma cells can form immune complexes with cognate antigens and activate macrophages and HSCs through Fc receptor-dependent responses, promoting the release of inflammatory mediators and pro-fibrotic signals such as TGF-β.21,22 Meanwhile, APLNR+ B cells exhibit enhanced migratory capacity and hepatic tissue infiltration and are associated with pro-fibrotic responses,23 suggesting that recruitment of B cells to injured tissue may strengthen their local interactions with T cells, macrophages, and HSCs. Thus, B cells can continuously amplify hepatic inflammation through 2 interconnected pathways: the B-cell antigen presentation–T-cell activation–myeloid-cell polarization axis and the antibody/immune complex–Fc receptor–myeloid-cell activation axis.
In contrast to pro-inflammatory and antibody-mediated effector functions, Bregs suppress inflammatory responses through IL-10, TGF-β, and IL-35.22,26 IL-10 can restrain the production of pro-inflammatory mediators such as TNF-α and IL-6 by macrophages and contribute to the maintenance of metabolic homeostasis.42 When chronic lipid overload and inflammation reduce Breg abundance or impair their functional capacity,33 this immunoregulatory restraint is weakened, allowing pro-inflammatory B-cell responses to persist. During the MASH–HCC transition, IL-21–driven IgA+ B cells can further impair antitumor immune surveillance through immunosuppressive mechanisms,21,24,25 extending the pathological effects of B cells beyond inflammation and fibrosis to tumor immune evasion.
Collectively, these effects converge on 3 interconnected pathological nodes: hepatocellular injury, myeloid inflammation, and HSC activation. CD8+ T cells, Th17/Th1 cells, and B cells amplify hepatic inflammation and fibrosis through cytotoxicity, pro-inflammatory cytokines, and antibodies or immune complexes, whereas Tregs, Bregs, and Trm cells exert opposing effects through immunosuppression or selective elimination of activated HSCs. Persistent lipotoxicity, oxidative stress, and inflammation further remodel the metabolic and functional states of adaptive immune cells, thereby reinforcing the reciprocal interaction between immune responses and metabolic injury. This establishes an immune–metabolic positive-feedback loop that sustains MASH progression (Figure 1).
Adaptive immune cell–mediated regulation of hepatic steatosis, inflammation, and fibrosis in MASH. Schematic illustration showing how adaptive immune cells drive intrahepatic inflammation and fibrosis during MASH. Cytotoxic CD8+ T-cell subsets (CXCR6+ and IRF4 activity) induce autoaggressive killing and activate Kupffer cells and HSCs, whereas CD69+CD103− Trm cells promote HSC apoptosis via FasL. Th1 and Th17 cells aggravate inflammation, lipid accumulation, and GSDMD-mediated pyroptosis, with chronic lipid overload driving a Treg-to-Th17 phenotypic drift. B2 cells and plasma cell–derived IgG immune complexes further activate KCs and HSCs via PPAR-α suppression and Fc receptor engagement, while protective Breg functions become impaired. Reciprocal T–B cell interactions create an immunometabolic feed-forward loop that perpetuates MASH progression. Abbreviations: Breg, regulatory B cell; CD, cluster of differentiation; CXCR6, C-X-C chemokine receptor 6; FasL, Fas ligand; Fc, fragment crystallizable; GSDMD, gasdermin D; HSCs, hepatic stellate cells; IgG, immunoglobulin G; IRF4, interferon regulatory factor 4; MASH, metabolic dysfunction–associated steatohepatitis; PPAR-α, peroxisome proliferator–activated receptor alpha; Th1, T helper 1; Th17, T helper 17; Trm, tissue-resident memory T cells; Treg, regulatory T cell.
Nutrient excess, lipotoxicity, oxidative stress, and gut-derived signals in MASH continuously reshape the metabolic and transcriptional states of adaptive immune cells, thereby determining their functional plasticity. Current evidence suggests that this process involves 3 interconnected layers. First, glucose, lipid, and mitochondrial metabolic reprogramming provide the metabolic foundation for distinct effector states. Second, metabolite-dependent epigenetic regulation further stabilizes inflammatory or regulatory transcriptional programs. Third, the gut–liver axis continuously modifies the intrahepatic immune environment through microbial components and metabolites. Together, these mechanisms shape CD8+ T-cell cytotoxicity, exhaustion, and reparative functions; the Th1/Th17–Treg balance in CD4+ T cells; and the pro-inflammatory, antibody-mediated, and immunoregulatory states of B cells.
Persistent nutrient excess first alters the metabolic demands of T and B cells. Infiltrating CD8+ T cells in MASH livers exhibit increased expression of glycolytic enzymes, including HK2, PKM2, and LDHA.43–45 PKM2 activation not only sustains high glycolytic flux but also drives the secretion of pro-inflammatory cytokines such as IL-17A, IFN-γ, and TNF-α, thereby exacerbating hepatocellular inflammation.30 Similar enhancement of glycolysis occurs in B cells and promotes their transition from conventional antibody-producing cells toward a pro-inflammatory phenotype, characterized by increased production of TNF-α and IL-6. These changes can further promote CD8+ T-cell activation and Th17 differentiation, establishing a self-amplifying inflammatory network.46–48 Thus, glycolysis does not merely meet the bioenergetic demands of immune-cell proliferation but also contributes to the maintenance of persistent inflammatory adaptive immune responses in MASH.
Dysregulated lipid metabolism further determines the magnitude and persistence of T-cell activation. Enhanced SCAP-mediated de novo cholesterol synthesis can alter membrane cholesterol and lipid-raft homeostasis, thereby affecting TCR and BCR signaling and providing metabolic conditions that support sustained lymphocyte activation under chronic antigenic stimulation.49–51 Excess free fatty acids (FFAs) can initially promote mitochondrial ROS production in CD8+ T cells, thereby enhancing cytotoxicity and IFN-γ secretion. However, prolonged lipid overload produces the opposite effect. Fatty acid accumulation associated with hepatic 15-PGDH downregulation can impair the mitochondrial membrane potential and oxidative phosphorylation of CD8+ T cells, resulting in reduced effector function and compromised immune surveillance and potentially contributing to MASH-to-HCC progression.52 Thus, the magnitude and duration of lipid exposure may determine whether CD8+ T cells transition from a highly reactive cytotoxic state to a metabolically dysfunctional state. Lipotoxicity also disrupts CD4+ T-cell homeostasis, as endoplasmic reticulum (ER) stress and signaling pathways involving Nr4a and LTβR–TRAF3–RORC have been associated with enhanced Th17 differentiation and impaired Treg stability, thereby promoting a pro-inflammatory shift in CD4+ T-cell function.31,53
The functional states of B cells are likewise shaped by the metabolic microenvironment of MASH. Lipotoxicity and oxidative stress can promote B-cell activation and functional remodeling. Lipotoxicity-associated ER stress activates XBP-1 and promotes the differentiation of B cells into antibody-secreting cells.54 Meanwhile, oxidation-specific epitopes (OSEs) generated by lipid peroxidation, including antigens associated with oxidized low-density lipoprotein (ox-LDL), can be recognized by B cells and induce antibody responses against OSEs.55 These antibodies can bind free antigens to form large immune complexes, which are recognized by Fc receptors and internalized into MHC-dependent cross-presentation pathways, thereby promoting Th1 polarization of CD4+ T cells and subsequent production of IFN-γ and TNF-α.56–59
Beyond conventional glucose and lipid metabolic reprogramming, specific hepatic metabolic pathways can generate signals that selectively reshape CD8+ T-cell function. β-Hydroxybutyrate produced through BDH1-mediated ketone metabolism can suppress IRF4 activity in CD8+ T cells and thereby limit excessive activation.28 Conversely, PCK1 deficiency promotes the accumulation of the endogenous lipid-derived metabolite 12-HETE, which acts on CD8+ T cells and activates the BACH1–p38 MAPK signaling pathway, leading to functional impairment.60 These findings suggest that hepatic metabolic abnormalities influence immune cells not only through generalized lipotoxic stress but also through specific metabolites that establish selective hepatocyte–T-cell metabolic signaling axes (Figure 2).
Glucolipotoxicity-driven metabolic reprogramming of adaptive immune cells in MASH. Persistent exposure to high glucose, FFAs, ox-LDL, and OSEs drives metabolic remodeling across adaptive immune populations. In CD8+ T cells, glycolytic activation, cholesterol accumulation, and PCK1 deficiency trigger mitochondrial dysfunction and p38 MAPK-dependent exhaustion. In CD4+ T cells, cholesterol remodeling, ER stress, and the LTβR–TRAF3–RORC–Nr4a axis drive Th17 expansion while suppressing Tregs. In B cells, ER stress (XBP-1) and lipid antigens promote plasma cell and APLNR+ B cell differentiation—activating stellate cells and macrophages via immune complexes—while impairing IL-10-producing Bregs. Together, these alterations exacerbate lipotoxicity, inflammation, and MASH progression. Abbreviations: APLNR, apelin receptor; Bregs, regulatory B cells; ER, endoplasmic reticulum; FFAs, free fatty acids; IL-10, interleukin 10; LTβR, lymphotoxin beta receptor; MASH, metabolic dysfunction–associated steatohepatitis; MAPK, mitogen-activated protein kinase; Nr4a, nuclear receptor subfamily 4 group A; ox-LDL, oxidized low-density lipoprotein; OSEs, oxidation-specific epitopes; PCK1, phosphoenolpyruvate carboxykinase 1; p38 MAPK, p38 mitogen-activated protein kinase; RORC, RAR-related orphan receptor C; TRAF3, TNF receptor–associated factor 3; Tregs, regulatory T cells; XBP-1, X-box binding protein 1.
Metabolic reprogramming can further establish more persistent immune states by altering chromatin modifications and the stability of key transcription factors, thereby linking environmental cues to durable transcriptional programs. Metabolites such as acetyl-CoA, lactate, and 2-HG participate in histone acetylation, lactylation, and the regulation of α-ketoglutarate-dependent dioxygenases, respectively, thereby connecting cellular metabolic states with inflammatory gene expression and T-cell fate determination.
Acetyl-CoA serves as a major substrate for histone acetylation. Alterations in glycolytic and lipid metabolism can affect intracellular acetyl-CoA availability and are associated with increased H3K9ac enrichment at the Ifng locus and enhanced IFN-γ transcription in CD8+ T cells.43–45 Similar chromatin-opening mechanisms may support the sustained expression of inflammatory genes in B cells. Thus, metabolic substrate availability can prolong the transcriptional activity of inflammatory effector genes through histone acetylation, converting transient metabolic stimuli into relatively stable pro-inflammatory functional states.
Lactate and 2-HG further connect metabolic status with CD4+ T-cell functional differentiation. Lactate-associated H3K18la and H3K9la modifications have been implicated in the transcriptional regulation of inflammatory genes such as Ifng and Il17a.61,62 Conversely, stable expression of Foxp3 is essential for maintaining Treg identity, and its acetylation can enhance protein stability and support Treg function.63 2-HG generated through glutamine metabolism can competitively inhibit α-KG–dependent TET and JmjC family enzymes, thereby altering the epigenetic state associated with Foxp3 and restricting Treg differentiation while favoring the establishment of Th17 programs.64 Thus, metabolite-driven epigenetic remodeling provides a mechanistic basis for impaired Treg stability and acquisition of Th17-like functions and may sustain the CD4+ T-cell functional shift induced by the MASH microenvironment (Figure 3).
Metabolite-driven epigenetic remodeling of adaptive immune cells in MASH. Metabolites serve as substrates or regulators to drive epigenetic and transcriptional reprogramming in MASH. Acetyl-CoA and lactic acid promote histone acetylation (H3K9ac) and lactylation (H3K18la/H3K9la) of Ifng and Il17a, enhancing IFN-γ/IL-17A production in CD8+ T cells and B cells. Glutamine-derived 2-HG inhibits TET-mediated DNA demethylation at the Foxp3 locus, promoting Th17 differentiation while suppressing Treg differentiation. Together, these modifications drive adaptive immune dysfunction in MASH. Abbreviations: 2-HG, 2-hydroxyglutarate; Ac, acetyl; CD, cluster of differentiation; Foxp3, forkhead box P3; H3K9ac, histone H3 lysine 9 acetylation; H3K9la, histone H3 lysine 9 lactylation; H3K18la, histone H3 lysine 18 lactylation; IFN-γ, interferon gamma; IL-17A, interleukin 17A; MASH, metabolic dysfunction–associated steatohepatitis; TET, ten-eleven translocation; Treg, regulatory T cell.
The gut–liver axis provides continuous exogenous signals that shape adaptive immune plasticity. Following disruption of the intestinal barrier, microbial components, bacteria-derived vesicles, and microbial metabolites can enter the liver through the portal circulation and directly or indirectly alter T-cell and B-cell activation, differentiation, and metabolic states through antigen-presenting cells. Unlike intrahepatic lipotoxicity, these signals reflect alterations in the distal intestinal ecosystem and can therefore continuously remodel the hepatic adaptive immune environment.
Microbial signals resulting from intestinal barrier disruption can simultaneously affect T and B cells. Recent studies have shown that intestinal TM6SF2 deficiency compromises barrier integrity and markedly increases portal LPS levels, which in turn promotes CD8+ T-cell exhaustion and enhances IgA+ plasma-cell responses.24,65–67 Intestinal IL-18 dysregulation caused by IL-18BP deficiency can also disrupt Reg3g-dependent and MUC2-dependent barrier homeostasis, promote the expansion of pathogenic bacteria, and exacerbate hepatic inflammation and fibrosis through inflammatory signals such as TNF-α and IL-6.68 Bacterial extracellular vesicles (BEVs) can carry bacterial proteins and nucleic acids into the liver, where they are taken up by APCs, enhance antigen presentation, and promote inflammatory activation of CD8+ T cells.69 These findings indicate that gut-derived signals can promote both persistent immune activation and functional dysfunction under chronic stimulation, with the outcome depending on the type, intensity, and duration of the signal.
In addition to microbial components, nonphysiological metabolites generated by alterations in the gut microbiota can enter the liver and further modulate adaptive immune functions. Microbiota alterations associated with TM6SF2 deficiency may increase the potential for LPA production, and portal delivery of LPA can influence T-cell migration, activation, and metabolic programs.65–67 Conversely, certain commensal bacteria, such as Bacteroides fragilis, produce polysaccharide A (PSA), which can be recognized by dendritic cells and locally promote Treg expansion to maintain immune tolerance.70 However, during MASH progression, gut-derived metabolites, including short-chain fatty acids (SCFAs) and secondary bile acids (BAs), can modulate T-cell polarization through the FXR/TGR5 signaling axis and metabolic pathways involving fatty acid transporters such as CD36.71,72 Thus, alterations in the gut microbiota can reshape the balance between pro-inflammatory Th17/Th1 responses and regulatory Treg responses and, together with intrahepatic metabolic stress, contribute to the establishment of adaptive immune states in MASH (Figure 4).
Gut–liver axis–mediated immune reprogramming in MASH progression. Gut dysbiosis and intestinal barrier dysfunction increase the portal delivery of microbial products and metabolites, including BAs, SCFAs, LPS, IL-18, LPA, BEVs, and PSA. These gut-derived signals reshape hepatic adaptive immunity by modulating APCs, CD8+ T cells, Treg cells, and B cells, thereby contributing to chronic inflammation and MASH progression. Abbreviations: APCs, antigen-presenting cells; BAs, bile acids; BEVs, bacterial extracellular vesicles; IL-18, interleukin 18; LPA, lysophosphatidic acid; LPS, lipopolysaccharide; MASH, metabolic dysfunction–associated steatohepatitis; PSA, polysaccharide A; SCFAs, short-chain fatty acids; Tregs, regulatory T cells.
Overall, adaptive immune plasticity in MASH is jointly shaped by local metabolic stress, metabolite-dependent epigenetic regulation, and gut-derived signals. Glycolytic and lipid metabolism establishes the metabolic basis for immune-cell activation and functional persistence; metabolites such as acetyl-CoA, lactate, and 2-HG further stabilize inflammatory or regulatory transcriptional programs; and the gut–liver axis continuously alters the hepatic input of antigens, microbial components, and metabolites. These signals ultimately converge on CD8+ T-cell cytotoxicity and dysfunction, the Th17/Treg balance in CD4+ T cells, and the effector and regulatory functions of B cells, thereby providing a mechanistic basis for the dynamic remodeling of adaptive immune states in MASH.
CONCLUSION
Adaptive immunity in MASH is not dominated by fixed T-cell or B-cell subsets but rather exhibits substantial functional plasticity in response to changes in the metabolic milieu and disease stage. This plasticity is reflected in the dynamic balance between pathogenic and reparative functions of CD8+ T cells, the dysregulation of the Treg/Th17 axis among CD4+ T cells, and the functional remodeling of B cells toward pro-inflammatory or immunoregulatory states. Together, these dynamic functional states constitute the cellular basis through which adaptive immunity contributes to MASH.
Distinct immune states are translated into divergent disease outcomes through specific effector mechanisms. Pathogenic CD8+ T cells directly exacerbate hepatocellular injury through aberrant cytotoxicity, whereas Th17/Th1-associated inflammatory cytokines promote myeloid-cell recruitment, hepatocellular metabolic dysfunction, and hepatic stellate cell activation. B cells further amplify inflammation and fibrosis through antigen presentation, cytokine production, and antibody- and immune complex-mediated responses. Conversely, Treg- and Breg-mediated immunoregulation, together with the capacity of tissue-resident CD8+ T cells to eliminate activated HSCs, can restrain inflammation and promote tissue repair. Thus, the impact of adaptive immune plasticity on MASH depends on the effector outputs and cellular targets associated with distinct functional states and ultimately converges on key pathological processes, including hepatocellular injury, myeloid inflammation, and fibrotic remodeling.
These functional states are continuously shaped by metabolic and microenvironmental signals. Reprogramming of glucose, lipid, and mitochondrial metabolism alters the energetic and substrate basis required for T-cell and B-cell activation and functional maintenance. Metabolites such as acetyl-CoA, lactate, and 2-HG further regulate inflammatory or immunoregulatory transcriptional programs through epigenetic mechanisms, whereas microbiota-derived components and metabolites from the gut–liver axis further modulate the activation, differentiation, and functional persistence of intrahepatic immune cells. Consequently, the metabolic shaping and reprogramming of adaptive immune states are reciprocally coupled with the effects of reprogrammed adaptive immune cells on hepatic pathology, forming an integrated immune–metabolic network that can either sustain MASH progression or contribute to disease resolution.
Despite these advances, direct and systematic causal evidence tracking T-cell and B-cell state transitions throughout MASH progression remains limited. Moreover, some of the proposed metabolic and epigenetic mechanisms have been established primarily in specific experimental models or other immune contexts. Future studies should integrate single-cell and spatial multi-omics, TCR/BCR clonal tracking, lineage tracing, and cell type–specific genetic manipulation to define the temporal dynamics and causal relationships underlying adaptive immune-state transitions across different stages of MASH. Particular attention should be given to the dynamic interactions between T and B cells and hepatocytes, HSCs, and myeloid cells. Such approaches may help identify the critical immune states and regulatory nodes that truly determine MASH progression, disease resolution, and the transition from MASH to HCC.